课题基金 / 基金详情

Basic studies on TOPK as a target molecule of cancer

Basic studies on TOPK as a target molecule of cancer
TOPK作为癌症靶分子的基础研究
批准号:
20590401
负责人:
ABE Yasuhito
金额:
$2.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010

项目摘要

项目成果

ABE Yasuhito的其他基金

相似基金

相关文献

中文摘要
翻译
目的:一种MAPKK样有丝分裂蛋白激酶TOPK在癌细胞的生长和运动中起着关键作用。抗HER2单抗的临床应用证明,EGF-R/HER2通过MAPK和PI3K信号通路在乳腺癌细胞的增殖和侵袭中发挥重要作用。RAF是MAPK信号通路中的重要成员,它与TOPK结合,但这种相互作用的意义尚未阐明。实验设计:分析TOPK在临床乳腺癌组织中的表达,并从TOPK和Raf的角度探讨乳腺癌细胞中MAPK信号转导途径。结果:免疫组织化学分析结果显示,TOPK的峰值表达强度与乳腺浸润性导管癌的组织学分级有关。我们的结果提示,RAF通过上调RAS与RAF的结合,使TOPK在Thr-198处磷酸化,而TOPK通过上调RAS与RAF的结合来增强MAPK信号。结论:TOPK可能通过EGF-R/HER2信号通路在乳腺癌的恶性潜能中发挥重要作用。这项研究表明,TOPK可以成为未来乳腺癌治疗的分子靶点。
英文摘要
Purpose: A MAPKK-like mitotic protein kinase, TOPK, plays a pivotal role in the growth and movement of cancer cells. As is evidenced by clinical application of anti-HER2-monoclonal antibody, EGF-R/HER2 mediates an important signaling in the proliferation and invasion of breast cancer cells through MAPK- and PI3K- signaling. Raf, an imperative member of MAPK signaling, binds to TOPK, although, significance of this interaction has not been elucidated. In this study, we analyzed expression of TOPK and investigated biological significance of TOPK-Raf interaction using breast cancer cells.Experimental Design: We analyzed the expression of TOPK in the clinical breast cancer tissues and investigated MAPK-signaling from the aspect of TOPK and Raf in breast cancer cells.Results: Immunohistochemical analysis revealed that the peak-expression intensity of TOPK correlated with the Histologic Grade of human invasive ductal carcinoma of breast. Our results suggested that Raf phosphorylates TOPK at Thr-198, a critical residue for kinase activity of TOPK and that TOPK enhances MAPK signaling by upregulating Ras binding to Raf.Conclusions: TOPK is indicated to play an important role in the malignant potential of breast cancer via EGF-R/HER2 signaling. This study suggests that TOPK can be a molecular target for breast cancer therapy in the future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/j.1365-2443.2009.01321.x
发表时间: 2009-08
期刊: Genes to Cells
影响因子: 2.1
作者: [T. Takeuchi;T. Kudo;K. Ogata;Michito Hamada;Megumi Nakamura;K. Kito;Y. Abe;Norifumi Ueda;Masayuki Yamamoto;J. D. Engel;Satoru Takahashi]
通讯作者: T. Takeuchi;T. Kudo;K. Ogata;Michito Hamada;Megumi Nakamura;K. Kito;Y. Abe;Norifumi Ueda;Masayuki Yamamoto;J. D. Engel;Satoru Takahashi
Serum anti-PDIK1L autoantibody as a novel marker for endometriosis.
血清抗 PDIK1L 自身抗体作为子宫内膜异位症的新型标志物。
DOI: 10.1016/j.fertnstert.2010.03.008
发表时间: 2010
期刊: Fertility and sterility
影响因子: 6.7
作者: [M. Nabeta, Y. Abe, Ryuma Haraguchi, K. Kito, Y. Kusanagi, Masaharu Ito]
通讯作者: Masaharu Ito
ADP-ribosylation factor like 7(ARL7)interacts with α-tubulin and modulates intracelluar vesicular transport
ADP-核糖基化因子 7 (ARL7) 与 α-微管蛋白相互作用并调节细胞内囊泡运输
DOI: --
发表时间: 2009
期刊: Biochemical and Biophysical Research Communications 384
影响因子: --
作者: [Wei, et al.]
通讯作者: et al.
Functional analysis of a Novel Human Protein Kinase, Nori-2p (MRPK) in the Proliferation of Cancer Cells
  • 批准号:
    11671165
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $1.92万
  • 财政年份:
    1999
  • 负责人:
    ABE Yasuhito
  • 依托单位:
LAK細胞の発現する膜結合型リンフォトキシンの癌細胞障害活性の解析
  • 批准号:
    05807106
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 资助金额:
    $1.22万
  • 财政年份:
    1993
  • 负责人:
    ABE Yasuhito
  • 依托单位:
国内基金
海外基金
HP靶向及TCb化疗联合乳癌术后方在HER2阳性乳腺癌患者中的前瞻性研究
  • 批准号:
    2024QN036
  • 项目类别:
    省市级项目
  • 资助金额:
    4.0万元
  • 批准年份:
    2024
  • 负责人:
    吴鸣远
  • 依托单位:
circEMCN编码多肽EMCN-81激活STAT3/VEGF通路调控炎性乳癌血管生成促进恶性进展的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    林颖
  • 依托单位:
CTSK调控ACSs-乳腺癌细胞交互功能促进脂肪移植乳癌术后重建的机制研究